CAS 1469924-27-3: Atglistatin

Atglistatin is a fatty acid with potent physiological activities. It has been shown to have significant effects on energy metabolism, pancreatitis, and cardiac function. Atglistatin binds to effector proteins that are involved in the regulation of cardiac contractility and the distribution of lipid in adipose tissue. These effects are mediated by its ability to inhibit protein kinase C (PKC) activity. The PKC family of protein kinases is important for regulating a variety of cellular functions such as cell growth, differentiation, and apoptosis. Atglistatin also inhibits the production of reactive oxygen species (ROS) in vitro by decreasing the expression of NADPH oxidase subunits p47phox and p67phox. This drug also has been shown to increase insulin sensitivity in vitro.

Atglistatin

Atglistatin: ATGL inhibitor, IC50 ~0.7 μM, inhibits lipolysis, non-toxic up to 50 μM.